






## Advisory Committee on Immunization Practices (ACIP)

# ACIP: Guidance for Health Economics Studies

These procedures should be followed for economic analyses to be presented to an ACIP Work Group or to the ACIP, effective as of the ACIP meeting of October 23-24, 2019.

Cost-effectiveness and other types of economic analyses are frequently presented during meetings of ACIP Work Groups (WGs) and the ACIP. The *Guidance for Health Economics Studies Presented to the ACIP, 2019 Update* (Guidance) was developed to ensure that economic data presented to the WGs and to the ACIP are uniform in presentation, understandable, and of the highest quality. The Guidance mandates a technical review of any economic study that is being considered for presentation. Economic study materials that are being submitted for review must include two items: (1) a document or report that describes the methods and results of the study, and (2) a slide set and/or other presentation materials.

- A detailed description of the materials to be presented, the timeline for submission, and the review process may be found in: [ACIP Guidance for Health Economics Studies, 2019 Update](#)  [21 pages]
  - The original, 2008 version of the Guidance available here: [ACIP Guidance for Health Economics Studies](#)  [9 pages]
- A template for preparation of presentation slides may be found in: [ACIP Guidance for Presentation Slides for Health Economics Studies](#)  [18 slides]

The report and presentation materials must be submitted to the relevant ACIP WG Chair and CDC Lead staff person no later than 8 weeks before the presentation is to be made at an ACIP WG meeting.

## Selected\* publications of health economic modeling studies

Vaccine	MMWR publication date	Vaccine recommendations published in MMWR	Economic model publications
Pneumococcal	September 2022	<a href="#">Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022</a>	<a href="#">Public health impact and cost-effectiveness of 15-valent pneumococcal conjugate vaccine use among the pediatric population of the United States</a> 
Hepatitis B	April 2022	<a href="#">Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022</a>	<a href="#">Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults</a> 
Zoster (Shingles)	January 2022	<a href="#">Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022</a>	<a href="#">Cost-Effectiveness Analysis of Vaccination With Recombinant Zoster Vaccine Among Hematopoietic Cell Transplant Recipients and Persons With Other Immunocompromising Conditions Aged 19 to 49 Years</a> 
Dengue	December 2021	<a href="#">Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021</a>	<a href="#">Cost-effectiveness of dengue vaccination in Puerto Rico</a> 
Tdap	January 2020	<a href="#">Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2019</a>	<a href="#">Economic impact of implementing decennial tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccination in adults in the United States</a> 
Pneumococcal	November 2019	<a href="#">Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices</a>	<a href="#">Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program</a> 
			<a href="#">Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions</a> 

Vaccine	MMWR publication date	Vaccine recommendations published in MMWR	Economic model publications
HPV	August 2019	Human Papillomavirus Vaccination for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices	Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States <a href="#">↗</a>
			Cost-effectiveness of HPV vaccination for adults through age 45 years in the United States: Estimates from a simplified transmission model <a href="#">↗</a>
Japanese Encephalitis	July 2019	Japanese Encephalitis Vaccine: Recommendations of the Advisory Committee on Immunization Practices	Comparative economic analysis of strategies for Japanese encephalitis vaccination of U.S. travelers <a href="#">↗</a>
Zoster (Shingles)	January 2018	Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines	A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations <a href="#">↗</a>
			Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults <a href="#">↗</a>
HPV	December 2016	Use of a 2-Dose Schedule for Human Papillomavirus Vaccination — Updated Recommendations of the Advisory Committee on Immunization Practices	Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis <a href="#">↗</a>
HPV	March 2015	Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices	Health and Economic Impact of Switching From a 4-Valent to a 9-Valent HPV Vaccination Program in the United States <a href="#">↗</a>
			The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model <a href="#">↗</a>
			Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine <a href="#">↗</a>
Meningococcal	March 2013	Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP)	MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: A decision analysis approach <a href="#">↗</a>
Pneumococcal	October 2012	Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)	Cost-effectiveness of administering 13-valent pneumococcal conjugate vaccine in addition to 23-valent pneumococcal polysaccharide vaccine to adults with immunocompromising conditions <a href="#">↗</a>
HPV	December 2011	Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males — Advisory Committee on Immunization Practices (ACIP), 2011	Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States <a href="#">↗</a>
			The cost-effectiveness of male HPV vaccination in the United States <a href="#">↗</a>
Tdap	October 2011	Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (Tdap) in Pregnant Women and Persons Who Have or Anticipate Having Close Contact with an Infant Aged <12 Months — Advisory Committee on Immunization Practices (ACIP), 2011	Pregnancy Dose Tdap and Postpartum Cocooning to Prevent Infant Pertussis: A Decision Analysis <a href="#">↗</a>
Meningococcal	August 2007	Revised Recommendations of the Advisory Committee on Immunization Practices to Vaccinate All Persons Aged 11–18 Years with Meningococcal Conjugate Vaccine	Economics of an Adolescent Meningococcal Conjugate Vaccination Catch-up Campaign in the United States <a href="#">↗</a>
Varicella	June 2007	Prevention of Varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP)	An Economic Analysis of the Universal Varicella Vaccination Program in the United States <a href="#">↗</a>
			Cost-effectiveness of a Routine Varicella Vaccination Program for US Children <a href="#">↗</a>
HPV	March 2007	Quadrivalent human papillomavirus vaccine; recommendations of the Advisory Committee on Immunization Practices (ACIP)	Cost-effectiveness of Human Papillomavirus Vaccination in the United States <a href="#">↗</a>
Hepatitis A	May 2006	Prevention of Hepatitis A Through Active or Passive Immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)	Cost-Effectiveness of Routine Childhood Vaccination for Hepatitis A in the United States <a href="#">↗</a>

Vaccine	MMWR publication date	Vaccine recommendations published in MMWR	Economic model publications
Meningococcal	March 2005	<a href="#">Prevention and Control of Meningococcal Disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)</a>	<a href="#">Vaccinating first-year college students living in dormitories for meningococcal disease: an economic analysis</a>  <a href="#">Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States</a>  <a href="#">Should college students be vaccinated against meningococcal disease? A cost-benefit analysis</a> 

\*The table does not include all publications of models presented to ACIP; e.g., industry/sponsor models are not included.

Last Reviewed: October 23, 2019